12:00 AM
 | 
Jan 10, 2000
 |  BC Week In Review  |  Company News  |  Deals

Ligand, Pharmaceutical Partners L.L.C. deal

LGND's Seragen Inc. subsidiary (Hopkinton, Mass.) sold to Pharmaceutical Partners its royalty rights to Zenapax daclizumab antibody to treat kidney transplant rejection, owned by F. Hoffman-La Roche Ltd. (Basel, Switzerland), and

Read the full 165 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >